30 completed, 10 terminated, 6 unknown, 4 recruiting. 30 Phase 2, 20 Phase 1, 4 Not applicable, 4 Phase 3.
Follow Carcinoma, Small Cell: new trials by email Literature Review of Carcinoma, Small Cell trials Research Report on Carcinoma, Small Cell
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01) BL-M14D1 and Atezolizumab, Carboplatin+ Etoposide + Atezolizumab followed by Atezolizumab and Lurbinectedin - Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer | Phase 3 | Recruiting | SystImmune Inc. | 550 | 2026-08-04 | 2026-10-15 |
| Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer Tarlatamab, Sacituzumab Govitecan - Extensive-Stage Small Cell Lung Cancer, Extrapulmonary Neuroendocrine Carcinoma | Phase 1 / Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2026-04-25 | 2026-04-28 | |
| Penfluridol for Relapsed/Refractory Small Cell Cancers Penfluridol Monotherapy for Relapsed/Refractory Small-Cell Lung or Cervical Cancer - Small Cell Carcinoma, Small Cell Carcinoma of Lung | Phase 1 / Phase 2 | Not yet recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 33 | 2025-10-01 | 2025-10-03 |
| ALG-LungCancerRegistry (SAFRO2202) Observational Data Collection - Lung Neoplasms, Carcinoma, Non-Small-Cell Lung | Recruiting | Société Algérienne de Formation et de Recherche en Oncologie | 3750 | 2025-06-01 | 2025-09-16 | |
| Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring Oncological Follow-up - Stage I Testicular Seminoma, Stage I Testicular Nonseminomatous Germ Cell Tumor | Phase 2 | Recruiting | Centre Oscar Lambret | 88 | 2024-02-28 | 2026-03-18 |
| A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors vobramitamab duocarmazine 2.0 mg (Arm A), vobramitamab duocarmazine 2.7 mg (Arm B), vobramitamab duocarmazine - Castration-Resistant Prostatic Cancer, Androgen-Independent Prostatic Cancer | Phase 2 | Terminated | MacroGenics | 192 | 2023-06-13 | 2026-02-09 |
| Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx) Pleural Effusion, Malignant, Ascites, Malignant | Completed | Travera Inc | 72 | 2022-07-15 | 2026-04-13 | |
| Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer Apalutamide, Cetrelimab - Small Cell Neuroendocrine Carcinoma, Prostate Cancer | Phase 2 | Terminated | Rahul Aggarwal | 2 | 2022-03-16 | 2025-05-15 |
| Quantifying Systemic Immunosuppression to Personalize Cancer Therapy MDSC quantification - Melanoma, Breast Cancer | Recruiting | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 1000 | 2022-03-10 | 2025-05-02 | |
| Pembrolizumab in Small Cell Carcinoma of Ovary - Hypercalcemic Type Patient Pembrolizumab - Small Cell Carcinoma, Hypercalcaemic Type, Ovarian Cancer | Not applicable | Completed | University Health Network, Toronto | 1 | 2021-12-06 | 2026-06-23 |
| The Registry of Oncology Outcomes Associated With Testing and Treatment Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P) - Adenocarcinoma, Adenocystic Carcinoma | Completed | Taproot Health | 167 | 2021-05-05 | 2024-12-18 | |
| IMFINZI Study in Patients With Extensive Stage Small Cell Lung Cancer Carcinoma, Small Cell | Completed | AstraZeneca | 248 | 2021-04-22 | 2024-07-24 | |
| CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors CT-0508, Pembrolizumab - HER2-positive, Adenocarcinoma | Phase 1 | Unknown | Carisma Therapeutics Inc | 48 | 2021-02-02 | 2024-12-18 |
| A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype. BXCL701 plus Pembrolizumab, BXCL701 monotherapy - Prostate Cancer, Neuroendocrine Tumors | Phase 1 / Phase 2 | Completed | BioXcel Therapeutics Inc | 98 | 2019-02-12 | 2026-05-15 |
| RRx-001 Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond in Patients With Small Cell Lung Cancer RRx-001 + eLOOP Device, Cisplatin/carboplatin plus etoposide - Carcinoma, Small Cell Lung | Phase 3 | Terminated | EpicentRx, Inc. | 18 | 2018-12-24 | 2024-03-26 |
| M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers M7824, Topotecan, Temozolomide - Carcinoma, Small Cell, Lung Cancer | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 37 | 2018-09-11 | 2025-05-09 |
| Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors Ipilimumab, Nivolumab - Genitourinary Cancer, Adrenocortical Carcinoma | Phase 2 | Active not recruiting | Dana-Farber Cancer Institute | 100 | 2017-12-28 | 2026-07-23 |
| Comparable Study of Different Thoracic Radiotherapy Regimens for Extensive Stage Small Cell Lung Cancer high-dose TRT, standard-dose TRT - Carcinoma, Small Cell, Lung Neoplasms | Not applicable | Unknown | Chinese Academy of Medical Sciences | 186 | 2017-12-01 | 2019-04-04 |
| Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers CK-301 (cosibelimab) - Lung Neoplasms, Carcinoma, Non-Small-Cell Lung | Phase 1 | Active not recruiting | Checkpoint Therapeutics, Inc. | 272 | 2017-09-20 | 2025-02-03 |
| A Study to Assess Programmed Death Ligand-1 (PD-L1) Expression in Cytological Versus Histological Lung Cancer Specimens PD-L1 Immunocytochemistry (ICC), PD-L1 Immunohistochemistry (IHC) - Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell | Completed | Hoffmann-La Roche | 184 | 2017-05-03 | 2019-07-23 |
Showing 20 of 55. Sign in to see all of them.
Lung Neoplasms (25) · Small Cell Lung Carcinoma (24) · Carcinoma, Non-Small-Cell Lung (14) · Neoplasms (8) · Urinary Bladder Neoplasms (7) · Breast Neoplasms (6) · Ovarian Neoplasms (6) · Carcinoma, Renal Cell (5) · Esophageal Neoplasms (5) · Head and Neck Neoplasms (5) · Melanoma (5) · Mesothelioma (5) · Prostatic Neoplasms (5) · Colorectal Neoplasms (4)
Neoplasms by Histologic Type (54) · Neoplasms, Glandular and Epithelial (54) · Carcinoma (52) · Neoplasms (47) · Neoplasms by Site (46) · Lung Diseases (42) · Respiratory Tract Neoplasms (42) · Thoracic Neoplasms (42) · Respiratory Tract Diseases (41) · Bronchial Neoplasms (33) · Carcinoma, Bronchogenic (32) · Lung Neoplasms (17) · Urogenital Diseases (16) · Genital Diseases (14) · Male Urogenital Diseases (14)
Cisplatin (7) · Etoposide (6) · Carboplatin (4) · Pemetrexed (4) · Topotecan (4) · pembrolizumab (4) · Gemcitabine (3) · Paclitaxel (2) · RRx-001 (2) · Temozolomide (2) · belinostat (2) · 130-nm albumin-bound paclitaxel (1) · ARQ 197 (1) · Acetaminophen (1) · Arsenic Trioxide (1)
AHS Cancer Control Alberta (4) · National Cancer Institute (NCI) (4) · SCRI Development Innovations, LLC (3) · Eli Lilly and Company (2) · EpicentRx, Inc. (2) · Valerio Therapeutics (2) · Advaxis, Inc. (1) · Andarix Pharmaceuticals (1) · Astellas Pharma Inc (1) · AstraZeneca (1) · Bayer (1) · BioXcel Therapeutics Inc (1) · Boehringer Ingelheim (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Carisma Therapeutics Inc (1)
United States (33) · Canada (9) · Spain (7) · France (5) · United Kingdom (5) · China (4) · Italy (4) · Poland (4) · Australia (3) · Germany (3) · Belgium (2) · Czechia (2) · South Korea (2) · Algeria (1) · Bulgaria (1)
David R. Spigel, MD (3) · Anish Thomas, M.D. (2) · Bryan Oronsky, MD, PhD (2) · Don Yee, MD (2) · LuHua Wang, MD (2) · Albert Font, MD (1) · Alfredo Sanchez, Doctor (1) · Amir Hafeez, MD (1) · Ana Blasco Cordellat, MD (1) · Antonio Lorenzo, MD (1)
PMID 20521352, PMID 20521355, PMID 21663862, PMID 23370364, PMID 24491267, PMID 25230595, PMID 27142472, PMID 27566413, PMID 29149611, PMID 30523756, PMID 31231122, PMID 31509028, PMID 31533818, PMID 32188704, PMID 32303619, PMID 32534809, PMID 32860331, PMID 33216356, PMID 33337539, PMID 33415580, PMID 33427689, PMID 33491277, PMID 33569311, PMID 33770291, PMID 34241781, PMID 34725215, PMID 35618285, PMID 35999229, PMID 36441083, PMID 36920652, PMID 37568622, PMID 37848259, PMID 39726590, PMID 39920391, PMID 40212844, PMID 41143139, PMID 42114950, PMID 42342409, PMID 42820295
2004 (1), 2014 (1), K23CA164015 (1), P30CA015704 (1), U10CA021115 (1), U10CA180820 (1), U24CA196172 (1)